Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus VISTARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus VISTARIL.
BENADRYL vs VISTARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Category C
Category C
Antihistamine
Antihistamine